News

Hims Reaffirms 2025 Sales Guidance After Posting Quarterly Beat
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Fierce Healthcare10h
Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers struggles post market despite strong Q1 results and 2025 outlook
Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...
Modern Healthcare18h
Hims & Hers names Amazon exec as chief of operations
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Up 30% In A Week, HIMS Stock Is Just Getting Warmed Up
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims outlines 2030 targets with $6.5B revenue and $1.3B EBITDA projections
Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...